Company intelligence / Profile preview

AxoNeural Therapeutics

Cleveland, Ohio, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

AxoNeural Therapeutics is developing nanoparticle-based drug delivery systems for the treatment of traumatic spinal cord injury. The company has received recent grant funding ($198,000 from Ohio Third Frontier) to support commercialization efforts for its lead therapeutic candidate. No published clinical results are available yet, indicating the programs are likely in preclinical or very early clinical stages

Therapeutic areas: Neurology
Modalities: Nanoparticle-delivered drugs
Industry: Biotech

Drug pipeline

1 asset

Neupron

Preclinical

Beyond the preview

Go deeper on AxoNeural Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AxoNeural Therapeutics.

Explore the full profile